FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2006568976> ?p ?o ?g. }

• W2006568976 endingPage "166" @default.
• W2006568976 startingPage "157" @default.
• W2006568976 abstract "1 Palmitaldehyde, olealdehyde and linolealdehyde acetal phosphatidic acids induced rapid shape change and dose-dependent biphasic aggregation of human platelets in platelet-rich plasma; aggregation was reversible at low doses and irreversible at high doses of the acetal phosphatidic acids. The palmitaldehyde congener elicited monophasic dose-dependent aggregation of sheep platelets in platelet-rich plasma. 2 The threshold concentration for palmitaldehyde acetal phosphatidic acid (PGAP)-induced platelet aggregation was 2.5–5 μM for human platelets and 0.25–0.5 μM for sheep platelets. PGAP was 4–5 times as potent versus human platelets as the olealdehyde and linolealdehyde acetal phosphatidic acids, which were equipotent. 3 PGAP-induced irreversible aggregation of [14C]-5-hydroxytryptamine ([14C]-5-HT)-labelled human platelets in platelet-rich plasma was accompanied by release of 44.0 ± 2.4% (s.e.) of the platelet [14C]-5-HT; reversible aggregation was not associated with release. In contrast, PGAP-induced release of [14C]-5-HT-labelled sheep platelets was dose-dependent. 4 The adenosine diphosphate (ADP) antagonist, 2-methylthio-AMP, and the cyclo-oxygenase inhibitor, aspirin, abolished PGAP-induced second phase aggregation and release in human platelets but did not affect the first, reversible, phase of aggregation. Both the first and second phases of PGAP-induced aggregation were abolished by chlorpromazine, by the phospholipase A2 inhibitor, mepacrine, and by nmolar concentrations of prostaglandin E1 (PGE1); these agents abolished the second, but not the first phase of ADP-induced aggregation. 5 The related phospholipids, lecithin, lysolecithin and phosphatidic acid, at < 100 μM, neither induced aggregation of human platelets in platelet-rich plasma, nor modified PGAP-induced aggregation; 1-palmityl lysophosphatidic acid elicited aggregation of human platelets at a threshold concentration of 100 μM. 6 It is concluded that the acetal phosphatidic acids induce platelet aggregation per se by direct action at the platelet membrane, and that the acetal function is of primary importance in their potent platelet-stimulating activity. Moreover, as the acetal phosphatidic acids are the major components of the smooth muscle-contracting acidic phospholipid tissue extract ‘Darmstoff’ (Vogt, 1949), their potent platelet-aggregating properties may be of physiological or pathological significance." @default.
• W2006568976 created "2016-06-24" @default.
• W2006568976 creator A5002837770 @default.
• W2006568976 creator A5011473652 @default.
• W2006568976 creator A5032100053 @default.
• W2006568976 creator A5051052349 @default.
• W2006568976 date "1983-05-01" @default.
• W2006568976 modified "2023-09-26" @default.
• W2006568976 title "Acetal phosphatidic acids: novel platelet aggregating agents" @default.
• W2006568976 cites W1542584079 @default.
• W2006568976 cites W1893528652 @default.
• W2006568976 cites W1965384242 @default.
• W2006568976 cites W1980791301 @default.
• W2006568976 cites W1983178353 @default.
• W2006568976 cites W1993882511 @default.
• W2006568976 cites W1994613176 @default.
• W2006568976 cites W2008862271 @default.
• W2006568976 cites W2035062956 @default.
• W2006568976 cites W2051140610 @default.
• W2006568976 cites W2066887655 @default.
• W2006568976 cites W2076082954 @default.
• W2006568976 cites W2076095413 @default.
• W2006568976 cites W2078995986 @default.
• W2006568976 cites W2084373177 @default.
• W2006568976 cites W2120055715 @default.
• W2006568976 cites W2122822427 @default.
• W2006568976 cites W2212849247 @default.
• W2006568976 cites W2225582428 @default.
• W2006568976 cites W2271112592 @default.
• W2006568976 cites W2410754138 @default.
• W2006568976 cites W2417081495 @default.
• W2006568976 cites W2464644489 @default.
• W2006568976 cites W2531807109 @default.
• W2006568976 cites W334592368 @default.
• W2006568976 cites W1981983144 @default.
• W2006568976 doi "https://doi.org/10.1111/j.1476-5381.1983.tb10508.x" @default.
• W2006568976 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2044846" @default.
• W2006568976 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/6871540" @default.
• W2006568976 hasPublicationYear "1983" @default.
• W2006568976 type Work @default.
• W2006568976 sameAs 2006568976 @default.
• W2006568976 citedByCount "9" @default.
• W2006568976 countsByYear W20065689762015 @default.
• W2006568976 countsByYear W20065689762023 @default.
• W2006568976 crossrefType "journal-article" @default.
• W2006568976 hasAuthorship W2006568976A5002837770 @default.
• W2006568976 hasAuthorship W2006568976A5011473652 @default.
• W2006568976 hasAuthorship W2006568976A5032100053 @default.
• W2006568976 hasAuthorship W2006568976A5051052349 @default.
• W2006568976 hasBestOaLocation W20065689761 @default.
• W2006568976 hasConcept C126322002 @default.
• W2006568976 hasConcept C12927208 @default.
• W2006568976 hasConcept C181199279 @default.
• W2006568976 hasConcept C185592680 @default.
• W2006568976 hasConcept C2776551241 @default.
• W2006568976 hasConcept C2776909261 @default.
• W2006568976 hasConcept C2777399203 @default.
• W2006568976 hasConcept C2778918659 @default.
• W2006568976 hasConcept C2779564620 @default.
• W2006568976 hasConcept C2993802102 @default.
• W2006568976 hasConcept C41625074 @default.
• W2006568976 hasConcept C55493867 @default.
• W2006568976 hasConcept C6182249 @default.
• W2006568976 hasConcept C71240020 @default.
• W2006568976 hasConcept C71924100 @default.
• W2006568976 hasConcept C89560881 @default.
• W2006568976 hasConceptScore W2006568976C126322002 @default.
• W2006568976 hasConceptScore W2006568976C12927208 @default.
• W2006568976 hasConceptScore W2006568976C181199279 @default.
• W2006568976 hasConceptScore W2006568976C185592680 @default.
• W2006568976 hasConceptScore W2006568976C2776551241 @default.
• W2006568976 hasConceptScore W2006568976C2776909261 @default.
• W2006568976 hasConceptScore W2006568976C2777399203 @default.
• W2006568976 hasConceptScore W2006568976C2778918659 @default.
• W2006568976 hasConceptScore W2006568976C2779564620 @default.
• W2006568976 hasConceptScore W2006568976C2993802102 @default.
• W2006568976 hasConceptScore W2006568976C41625074 @default.
• W2006568976 hasConceptScore W2006568976C55493867 @default.
• W2006568976 hasConceptScore W2006568976C6182249 @default.
• W2006568976 hasConceptScore W2006568976C71240020 @default.
• W2006568976 hasConceptScore W2006568976C71924100 @default.
• W2006568976 hasConceptScore W2006568976C89560881 @default.
• W2006568976 hasIssue "1" @default.
• W2006568976 hasLocation W20065689761 @default.
• W2006568976 hasLocation W20065689762 @default.
• W2006568976 hasLocation W20065689763 @default.
• W2006568976 hasLocation W20065689764 @default.
• W2006568976 hasOpenAccess W2006568976 @default.
• W2006568976 hasPrimaryLocation W20065689761 @default.
• W2006568976 hasRelatedWork W1138617401 @default.
• W2006568976 hasRelatedWork W1535300883 @default.
• W2006568976 hasRelatedWork W1975788845 @default.
• W2006568976 hasRelatedWork W2006568976 @default.
• W2006568976 hasRelatedWork W2047344067 @default.
• W2006568976 hasRelatedWork W2048928818 @default.
• W2006568976 hasRelatedWork W2125484581 @default.
• W2006568976 hasRelatedWork W2272683735 @default.
• W2006568976 hasRelatedWork W2989014658 @default.

• next